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sidered all patients undergoing elective, urgent, or emergent PCI
at Mayo Clinic Rochester between 3/1/1998–3/31/2003 in analy-
ses. Clinical, angiographic, and outcome data were derived from
the Mayo Clinic PCI Registry. In-hospital PCI complications
included major adverse cardiac and cerebrovascular events
(MACCE) (deﬁned as death, myocardial infarction [MI], emer-
gent coronary bypass surgery, repeat PCI, or stroke) and bleed-
ing of clinical signiﬁcance. Administrative data was used to
estimate total costs (hospital and physician) in standardized, year
2004 constant-dollars. We used generalized linear modeling to
estimate the incremental costs associated with complications
adjusting for demographic, clinical, angiographic, and proce-
dural characteristics. RESULTS: 1071 (13.2%) of patients 
experienced at least one of the selected complications during hos-
pitalization. Patients experiencing complications were older,
more likely to present with emergent PCI, recent or prior MI,
multi-vessel disease, B2/C type lesions, and comorbid conditions
than patients who did not experience these events. Unadjusted
total costs were, on average, $27,865 ± $39,424 for patients who
experienced any complication compared to $12,279 ± $6796 for
those who were free of complications (p < 0.0001). Adjusted
mean total costs were $7000 higher for patients experiencing
complications compared with patients who were complication
free (95% CI of cost difference: $5,854, $8,145). Incremental
costs associated with only bleeding events, only MACCE, or 
for patients experiencing bleeding and MACCE events were
$5813, $5151, and $15,699, respectively (p < 0.0001). CON-
CLUSIONS: This observational study highlights the signiﬁcant
economic burden associated with in-hospital procedural compli-
cations. Interventions to reduce the risk of adverse events likely
enhance ﬁnancial as well as clinical performance.
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OBJECTIVE: The prevalence of VTE and its associated mor-
bidity and mortality is difﬁcult to assess. This is due to its often
silent nature, difﬁculty of diagnosis and follow up, and lack of
routine post-mortems. This is thought to result in marked under-
estimates of its true burden. VITA is the ﬁrst large-scale study
that aims to determine the burden of VTE at a European level.
METHODS: A modiﬁed incidence-based epidemiological model
was developed to estimate the number of VTE events and deaths
taking into consideration recurrence and complications. Separate
models were constructed for France, UK, Germany, Italy, Sweden
and Spain; the total number VTE events were extrapolated for
the EU. These comprehensive models were populated with pub-
lished literature when available and expert observation when
necessary. Both community-acquired and hospital-acquired
events were derived. The former were based on a large European
epidemiological study (EPI-GETBO) and the latter were derived
using a hospital episode statistics database in conjunction with
a “bottom-up” approach. RESULTS: The total annual burden
of VTE across the EU was estimated to be 641,275 symptomatic
deep-vein thromboses (DVT), and 382,550 pulmonary emboli
(PE). VTE-related deaths were estimated at 478,500. Of these
deaths, 34,450 (7%) patients had been diagnosed with VTE and
treated, 163,050 (34%) were estimated to be sudden fatal PE
and 281,000 (59%) followed undetected PE. These ﬁndings were
tested using probabilistic sensitivity analyses. CONCLUSIONS:
The VITAE study conﬁrms that VTE is a major public health
problem in the EU. Many of these events and deaths were sudden
or due to undetected disease. Given the availability of effective
VTE prophylaxis, many of these events and deaths are pre-
ventable. This is of particular importance in the medical setting
where the implementation of prophylaxis remains suboptimal.
Further research to estimate the impact of increased prophylaxis
use is urgently needed.
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OBJECTIVE: There are limited data documenting common
strategies used for inpatient thromboprophylaxis or describing
the costs associated with common treatment modalities. The aim
of the study was to assess treatment patterns, utilization of health
care resources and hospital costs associated with thrombopro-
phylaxis in real-world clinical practice in Poland. METHODS:
Data from inpatient records were collected prospectively for
patients hospitalized in 25 departments between 31.04.2004 and
31.05.2005. Stratiﬁed analyses were performed by baseline risk
of thrombosis and means of total cost for each group were cal-
culated, using participating hospitals account systems. Costs
comparisons related to risk groups were performed using non-
parametric tests with signiﬁcance level of 0.05. RESULTS: The
database contains information about 5348 patients. Of these
35% were general surgery, 23% medical, 15.3% vascular and
13% orthopedic surgery patients. 59% of patients were at
highest risk of VTE (I), 24% at high (II), 10% at moderate (III)
and 7% at low risk (IV). Thromboprophylaxis received 84%,
77%, 71% and 60% patients in I, II, III, and IV group, respec-
tively. Most admissions (76,%) involved LMHHs treatments,
administered for mean 10.2, 6.3, 6.0 and 5.8 days in group
I,II,III and IV respectively. Adverse events related to thrombo-
prophylaxis occurred in 2% of patients; 85% of these were
minor hemorrhages, 9% major hemorrhages, 2% thrombocy-
topenia. Post-discharge thromboprophylaxis was indicated for
34.6% patients, most frequently in patients after orthopedic
surgery (81.3%), trauma (66.3%) or cardiological hospitaliza-
tions (49%). The most common regimen in extended thrombo-
prophylaxis was LMWHs (77%). Mean cost of
thromboprophylaxis was 999 (+/-5964) PLN in I, 327 (+/-1598)
PLN in II, 260 (+/-695) PLN in III and 232 (+/-842) PLN in
group IV (1 EURO = 4 PLN, 2005) (p = 0.0001). CONCLU-
SION: Results from this study indicate that inpatient thrombo-
prophylaxis is in line with clinical guidelines. The risk
stratiﬁcation of hospitalized patients allows for the estimation of
costs.
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OBJECTIVES: Patients undergoing major orthopaedic proce-
dures such as hip fracture surgery (HFS) and total hip replace-
ment (THR) are at increased risk of developing venous
thromboembolic events (VTE). It was shown in the Penthifra
plus trial that extending fondaparinux prophylaxis from 1 week
to 4 weeks reduces the risk of VTE by 96%. Whether prolonged
